ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

NCT07542717 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic Cervical Cancer

Interventions

DRUG: Treatment

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University